Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review
Section snippets
Background
Nausea and vomiting represent a common side-effect of chemotherapy, potentially affecting 60–80% of oncology patients (ONS, 2014, de Boer-Dennert et al., 1997). Nausea is defined as the unpleasant feeling causing the desire to vomit, and can be accompanied by symptoms such as tachycardia, dizziness and weakness (Camp-Sorrell, 2005). Vomiting is defined as the contraction of the muscles of the abdomen and diaphragm that triggers the expulsion of stomach contents (Baker et al., 2005).
Identification of studies
This review adopts the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (Moher et al., 2010). A systematic search was conducted on MEDLINE, EMBASE and the National Health System Economic Evaluation Database (NHS EED). Reference lists of the most relevant retrieved articles were screened to find additional studies not identified through the database search. The search strategy was developed using the PICOS (Patient, Intervention, Comparator, Study) framework.
Literature search
A total of 394 studies were found through MEDLINE (285), EMBASE (55) and NHS EED databases (54). After duplicates removal (27) and addition of potentially relevant papers from bibliography search (30), 397 studies were screened by two reviewers. Sixty-seven studies were included in the final selection. Kappa statistic was good for title screening (0.78), moderate for the abstract screening phase (0.50) and good for full-text screening (0.74). Fig. 1 shows the selection process and reasons for
Discussion
CINV represents a common and serious side effect for oncology patients (Dikken and Wildman, 2013). Anxiety, poor nutrition, dehydration, difficulty to eat and even physical damage to the stomach are some of the consequences of CINV. Despite significant improvements thanks to the introduction of treatments in the 1990s, CINV remains a substantial problem for oncology patients (Grunberg et al., 2002) and with the rapid development of new chemotherapy treatments, it becomes more and more important
Author contributions
This review is a joint effort of all the co-authors and the paper has been written jointly by them. SS contributed to the design of the review, screening, review of the data and writing of the manuscript. BP contributed to the screening and extraction of the data and writing of the manuscript. RT contributed to the design of the review, to the final recommendations and to the writing of the manuscript. All authors have approved the final article.
Conflict of interest statement
We declare that none of the authors or their organisations has any conflict of interest in the publication of this paper.
Acknowledgements
This work was supported by an unrestricted grant from Helsinn Group. The authors were responsible for all content and Helsinn had no involvement in the development of this publication. The authors thank the anonymous reviewers for their insightful comments.
Silvia Sommariva is a researcher at the Centre for Research on Health and Social Care Management, Bocconi University. She graduated in Business Administration from Bocconi University, and obtained an MSc in Management of Public Administration and International Institutions from Bocconi University and a Master of Public Administration with major in health and social policy from State University of New York. Her main research areas of interest are policies related to biotechnologies in
References (96)
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
Ann. Oncol.
(2012)Treatment of nausea and emesis during cancer chemotherapy: Discrepancies between antiemetic effect and well-being
J. Pain Symptom Manage.
(2002)Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group
Eur. J. Cancer
(1995)Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life
Clin. Ther.
(1996)The real costs of emesis—an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer
Eur. J. Cancer
(1993)Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation
Biol. Blood Marrow Transplant.
(2001)The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers
Ann. Oncol.
(2004)International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice
Eur. J. Pharmacol.
(2014)- et al.
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
Ann. Oncol.
(2015) Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer
Crit. Rev. Oncol./Hematol.
(1999)
Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada
Support. Cancer Ther.
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group
Ann. Oncol.
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany
Eur. J. Cancer
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study
J. Pain Symptom Manage.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Int. J. Surg.
Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
Value Health
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Ann. Oncol.
Economics and health-related quality of life in antiemetic therapy: recommendations for trial design
Eur. J. Cancer
5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis
Drugs
Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost
Cancer Investig.
Evaluation of the efficacy of aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life with functional living index emesis
Balkan Med. J.
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
J. Clin. Oncol.
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium
Support. Care Cancer
Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients
J. Support. Oncol.
The pathophysiology of chemotherapy-induced nausea and vomiting
Gastroenterol. Nurs.
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy
Health Qual. Life Outcomes
The cost of chemotherapy-induced nausea and vomiting in Italy
Support. Care Cancer
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens
Cancer Chemother. Pharmacol.
Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy
Semin. Oncol.
Cost-effectiveness analysis of antiemetic treatment
Support. Care Cancer
Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment
J .Clin. Oncol.
Chemotherapy-induced nausea and vomiting: identifying and addressing unmet needs
J. Clin. Outcomes Manage.
The impact of 5-HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: systematic review of the literature
Am. Health Drug Benefits
Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting
Support. Care Cancer
Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting
Br. J. Cancer Suppl.
Systematic Reviews CRD’s Guidance for Undertaking Reviews in Health Care
Chemotherapy toxicities and management
Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong
Asia Pac. J. Clin. Oncol.
Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice–a longitudinal analysis
Support. Care Cancer
Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings
Support. Care Cancer
Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States
J. Med. Econ.
Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy
J. Support. Oncol.
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
Br. J. Cancer
Control of nausea and vomiting caused by chemotherapy
Cancer Nurs. Pract.
Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy
Int. J. Technol. Assess. Health Care
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron
Support. Care Cancer
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea
Support. Care Cancer
Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party
BMJ
Cited by (0)
Silvia Sommariva is a researcher at the Centre for Research on Health and Social Care Management, Bocconi University. She graduated in Business Administration from Bocconi University, and obtained an MSc in Management of Public Administration and International Institutions from Bocconi University and a Master of Public Administration with major in health and social policy from State University of New York. Her main research areas of interest are policies related to biotechnologies in healthcare, healthcare research funding policies and health economics.
Benedetta Pongiglione is a PhD student at the London School of Hygiene and Tropical Medicine. She obtained a MSc in Economic and Social Sciences from Bocconi University and went on to attend the European Doctoral School of Demography program. Her main research interest is the study of health inequalities, particularly inequalities in healthy ageing, with a focus on the role of health-related behaviours. She is currently developing a measurement model to estimate the burden of diseases and disability on mortality, and assess socioeconomic inequalities in healthy survival and the role of health-related behaviour in mediating this association.
Rosanna Tarricone is an Associate Professor at the Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy. She graduated in Business Administration from Bocconi University, obtained an MSc in Health Services Management and a PhD in Economics from the University of London. She is the Director of the Centre for Health and Social Care Management (CERGAS) at Bocconi University and the Scientific Director of the European Health Technology Institute for Socio-Economic Research. Her main areas of research include healthcare management, health economics, economic analysis of healthcare services, health policy and health technology assessment. Rosanna is a member of the International Association of Health Economics (iHEA), the International Health Technology Assessment (HTAi), and the International Society for Pharmacoeconomics and Outcome Research (ISPOR). She is the author of numerous papers and books on healthcare management and economics.